Page last updated: 2024-12-04

oxalic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Oxalic Acid: A strong dicarboxylic acid occurring in many plants and vegetables. It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine. It is used as an analytical reagent and general reducing agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxalic acid : An alpha,omega-dicarboxylic acid that is ethane substituted by carboxyl groups at positions 1 and 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID971
CHEMBL ID146755
CHEBI ID16995
MeSH IDM0029413

Synonyms (128)

Synonym
AKOS005449445
ethandisaeure
hooccooh
h2ox
CHEBI:16995 ,
ethane-1,2-dioic acid
NCIOPEN2_001202
NCIOPEN2_001042
NCIOPEN2_000770
NCIOPEN2_001022
oxaalzuur
nsc62774
acido ossalico
acide oxalique
nci-c55209
aquisal
oxiric acid
kyselina stavelova
nsc-62774
ethanedionic acid
oxalsaeure
wln: qvvq
aktisal
inchi=1/c2h2o4/c3-1(4)2(5)6/h(h,3,4)(h,5,6
ultraplast activate s 52
epa pesticide chemical code 009601
ethanedioic acid (9ci)
ccris 1454
ai3-26463
hsdb 1100
caswell no. 625
oxalic acid (8ci)
oxagel
oxd ,
kyselina stavelova [czech]
nsc 62774
oxaalzuur [dutch]
acido ossalico [italian]
acidum oxalicum
oxalsaeure [german]
einecs 205-634-3
acide oxalique [french]
brn 0385686
C00209
144-62-7
ethanedioic acid
oxalic acid
nsc115893
oxalic acid, purified grade, 99.999% trace metals basis
2HWG
1T5A
2DUA
1O4N
DB03902
oxalic acid, reagentplus(r), >=99%
oxalic acid, 98%
NCIOPEN2_008831
bdbm14674
STK379550
oxalic acid, puriss. p.a., anhydrous, >=99.0% (rt)
F1B1B2D7-C290-4CE6-8550-F25B202AFADE
CHEMBL146755
oxalic acid dianion
BMSE000106
FT-0657506
NCGC00249170-01
BBL003000
acid, oxalic
cas-144-62-7
dtxsid0025816 ,
NCGC00257376-01
tox21_303346
dtxcid805816
tox21_202122
NCGC00259671-01
S9354
c2h2o4
ec 205-634-3
unii-9e7r5l6h31
4-02-00-01819 (beilstein handbook reference)
9e7r5l6h31 ,
BP-21133
oxaliplatin impurity a [ep impurity]
oxalic acid [inci]
oxalic acid [mi]
oxalic acid [hsdb]
oxalic acid [vandf]
oxalic acid [who-dd]
oxalic acid anhydrous
oxalic acid 2 hydrate
tetradecanoic-d27acid
oxalicacid
mfcd00002573
CS-0013716
oxalic acid, anhydrous
F2191-0257
oxalic acid dihydrate acs
oxalic acid, purum, anhydrous, >=97.0% (rt)
oxalate standard for ic, 1.000 g/l in h2o, analytical standard
oxalic acid, saj first grade, >=97.0%
oxalic acid 2-hydrate
ethane-1,2-dioate
ethanedionate
anhydrous oxalic acid
oxalic acid (aqueous)
oxalic acid, vetec(tm) reagent grade, 98%
oxalic acid, lr, >=98%
oxalic acid, ar, >=99%
J-007978
oxalate standard for ic
oxalic acid, analytical standard
HY-Y0262
oxalic acid 10 microg/ml in acetonitrile
Q184832
STR01359
CCG-266020
wood bleach
48J ,
bis((2r)-azetidine-2-carbonitrile)
SB40938
bis(5-azaspiro[2.5]octan-8-ol)
bis(1-(3-methyloxetan-3-yl)ethan-1-amine)
SB40959
SB40985
EN300-16428
nci-55209
oxaliplatin impurity a (ep impurity)
oxalic acid alpha polymorph

Research Excerpts

Overview

Oxalic acid is a common antinutrient in the human diet, found in large quantities in spinach. It is an important pathogenicity-determinant of necrotrophic phytopathogenic fungi, such as Sclerotina sclerotiorum.

ExcerptReferenceRelevance
"Oxalic acid (OA) is a popular miticide used to control Varroa destructor (Mesostigmata: Varroidae) in western honey bee (Apis mellifera L.) (Hymenoptera: Apidae) colonies. "( Oxalic acid application method and treatment intervals for reduction of Varroa destructor (Mesostigmata: Varroidae) populations in Apis mellifera (Hymenoptera: Apidae) colonies.
Abou-Shaara, HF; Ellis, JD; Jack, C; Prouty, C; Stanford, B, 2023
)
3.8
"Oxalic acid is a common antinutrient in the human diet, found in large quantities in spinach. "( High and low oxalate content in spinach: an investigation of accumulation patterns.
Fatahi, R; Hassandokht, M; Mirahmadi, SF; Naghavi, MR; Rezaei, K, 2022
)
2.16
"Oxalic acid (OxA) is an end product in the oxidation of many organic compounds, and therefore is ubiquitous in the atmosphere and is often the most abundant organic species in ambient aerosols. "( Investigation on the hygroscopicity of oxalic acid and atmospherically relevant oxalate salts under sub- and supersaturated conditions.
Boreddy, SKR; Kawamura, K, 2018
)
2.19
"Oxalic acid is a naturally occurring metabolite in plants and a common constituent of all plant-derived human diets. "( Manipulation of oxalate metabolism in plants for improving food quality and productivity.
Datta, A; Irfan, M; Kumar, V, 2019
)
1.96
"Oxalic acid (OA) is an important pathogenicity-determinant of necrotrophic phytopathogenic fungi, such as Sclerotina sclerotiorum (S."( Overexpression of AtWRKY28 and AtWRKY75 in Arabidopsis enhances resistance to oxalic acid and Sclerotinia sclerotiorum.
Chen, X; Lin, G; Liu, J; Lu, G; Wang, A; Wang, Z, 2013
)
1.34
"As oxalic acid is a common metabolite in plants, we propose that attacked host cells are able to metabolize oxalic acid in the early infection stage and translocate it to their vacuoles where it is stored as calcium oxalate."( Oxalic acid has an additional, detoxifying function in Sclerotinia sclerotiorum pathogenesis.
Heller, A; Witt-Geiges, T, 2013
)
2.35
"Oxalic acid (OA) is an important pathogenic factor during early Sclerotinia sclerotiorum-host interaction and might work by reducing hydrogen peroxide production (H2 O2 ). "( Biocontrol agents-mediated suppression of oxalic acid induced cell death during Sclerotinia sclerotiorum-pea interaction.
Jain, A; Sarma, BK; Singh, A; Singh, HB; Singh, S, 2015
)
2.12
"Oxalic acid is a uremic retention molecule that has been extensively studied in the pathogenesis of calcium-oxalate stones."( The relationship between colonization of Oxalobacter formigenes serum oxalic acid and endothelial dysfunction in hemodialysis patients: from impaired colon to impaired endothelium.
Erdur, FM; Turkmen, K, 2015
)
1.37
"Oxalic acid is thought to be a key factor of the early pathogenicity stage in a wide range of necrotrophic fungi. "( Anion channel activity is necessary to induce ethylene synthesis and programmed cell death in response to oxalic acid.
Bouteau, F; Briand, J; Corbineau, F; Errakhi, R; Lehner, A; Meimoun, P; Rona, JP; Vidal, G, 2008
)
2
"Oxalic acid is thought to be a significant uremic toxin that participates in the pathogenesis of uremic syndrome. "( [Oxalic acid--important uremic toxin].
Derzsiová, K; Mydlík, M, 2010
)
2.71
"Oxalic acid (OA) is a secondary compound occurring in a wide range of plants consumed by ruminants, especially in saline lands or in arid and semi-arid regions. "( Impact of oxalic acid on rumen function and bacterial community in sheep.
Belenguer, A; Ben Bati, M; Frutos, P; Hervás, G; Toral, PG; Yáñez-Ruiz, DR, 2013
)
2.23
"Oxalic acid is a virulence factor of several phytopathogenic fungi, including Sclerotinia sclerotiorum (Lib.) de Bary, but the detailed mechanisms by which oxalic acid affects host cells and tissues are not understood. "( Oxalate production by Sclerotinia sclerotiorum deregulates guard cells during infection.
Guimarães, RL; Stotz, HU, 2004
)
1.77
"Oxalic acid is an end product of metabolism, and no significant degradation of oxalate occurs in mammals. "( Extrarenal clearance of oxalate increases with progression of renal failure in the rat.
Costello, JF; Sadovnic, MJ; Smith, M; Stolarski, C, 1992
)
1.73
"Oxalic acid is a competitive inhibitor of pyruvate reduction by this enzyme with apparent Ki of approximately equal to 0.41 mM."( Characterization of lactate dehydrogenase of Plasmodium knowlesi.
Dutta, GP; Ghatak, S; Pandey, VC; Saxena, N, 1986
)
0.99
"Oxalic acid is a fermentation product of Aspergillus. "( Oxalic acid level in bronchoalveolar lavage fluid from patients with invasive pulmonary aspergillosis.
Astier, A; Benoit, G; Bernaudin, JF; Cordonnier, C; Feuilhade de Chauvin, M, 1985
)
3.15

Effects

Oxalic acid has potential for use as a sanitizer to reduce populations of spoilage microorganisms naturally occurring on raw chicken. Oxalic Acid has diverse unrelated roles in plant metabolism, including pH regulation in association with nitrogen metabolism, metal ion homeostasis and calcium storage.

ExcerptReferenceRelevance
"Oxalic acid has a strong antibrowning activity. "( Kinetic study of oxalic acid inhibition on enzymatic browning.
Lee, CY; Moon, KD; Son, SM, 2000
)
2.09
"Oxalic acid has two functions in these redox reactions; the first is to provide the H"( Effects of oxalic acid on Cr(VI) reduction by phenols in ice.
Kang, C; Shang, D; Tian, T; Wang, N; Wang, Y; Xiao, K; Zhong, Y, 2019
)
1.63
"Oxalic acid has diverse unrelated roles in plant metabolism, including pH regulation in association with nitrogen metabolism, metal ion homeostasis and calcium storage."( Manipulation of oxalate metabolism in plants for improving food quality and productivity.
Datta, A; Irfan, M; Kumar, V, 2019
)
1.24
"Oxalic acid has potential for use as a sanitizer to reduce populations of spoilage microorganisms naturally occurring on raw chicken, thereby extending chicken shelf life."( Inhibitory effect of oxalic acid on bacterial spoilage of raw chilled chicken.
Anang, DM; Bakar, J; Beuchat, LR; Radu, S; Rusul, G, 2006
)
1.37
"An oxalic acid solution has been proposed as a conditioning agent for resin composite restorations in two commercial adhesive systems. "( Five year evaluation of class III composite resin restorations in cavities pre-treated with an oxalic- or a phosphoric acid conditioner.
Holm, C; Olofsson, AL; van Dijken, JW, 1999
)
0.92
"Oxalic acid has also been found to be involved in the attacking mechanism of several phytopathogenic fungi."( Oxalate decarboxylase from Collybia velutipes. Molecular cloning and its overexpression to confer resistance to fungal infection in transgenic tobacco and tomato.
Azam, M; Datta, A; Kesarwani, M; Mehta, A; Natarajan, K, 2000
)
1.03
"Oxalic acid has a strong antibrowning activity. "( Kinetic study of oxalic acid inhibition on enzymatic browning.
Lee, CY; Moon, KD; Son, SM, 2000
)
2.09

Actions

Oxalic acid plays a pivotal role in the virulence of the necrotrophic fungi Botrytis cinerea and Sclerotinia sclerotiorum. It lowers the pH of nearby environment and creates the favorable condition for the infection.

ExcerptReferenceRelevance
"Oxalic acid plays a pivotal role in the virulence of the necrotrophic fungi Botrytis cinerea and Sclerotinia sclerotiorum."( Mechanisms of plant protection against two oxalate-producing fungal pathogens by oxalotrophic strains of Stenotrophomonas spp.
Gárriz, A; Marina, M; Martinez, GA; Medina, AJ; Pieckenstain, FL; Romero, FM; Rossi, FR; Villarreal, NM, 2019
)
1.24
"Oxalic acid (OA) plays dual role in fungal pathogenicity in a concentration dependent manner. "( Proteometabolomic analysis of transgenic tomato overexpressing oxalate decarboxylase uncovers novel proteins potentially involved in defense mechanism against Sclerotinia.
Chakraborty, N; Chakraborty, S; Ghosh, R; Ghosh, S; Jawa, P; Narula, K; Sinha, A, 2016
)
1.88
"Oxalic acid plays major role in the pathogenesis by Sclerotinia sclerotiorum; it lowers the pH of nearby environment and creates the favorable condition for the infection. "( Isolation of oxalic acid tolerating fungi and decipherization of its potential to control Sclerotinia sclerotiorum through oxalate oxidase like protein.
Arora, DK; Singh, DP; Srivastava, AK; Yadav, S, 2012
)
2.19
"Oxalic acid plays a pivotal role in the adaptation of the soil microbe Pseudomonas fluorescens to aluminum (Al) stress. "( Modulation of TCA cycle enzymes and aluminum stress in Pseudomonas fluorescens.
Appanna, VD; Hamel, RD, 2001
)
1.75

Treatment

The oxalic acid pretreatment of deacetylated biomass was carried out and the hydrolysate directly used for ethanol production without detoxification. The treatment apparently alleviated CI development and membrane damage; maintained higher levels of ATP and ADP; increased activities of succinic dehydrogenase.

ExcerptReferenceRelevance
"Oxalic acid pretreated cotton linters was utilised as the model substrate for the prehydrolysis-soda anthraquinone process."( Cellulose degradation in alkaline media upon acidic pretreatment and stabilisation.
Nieminen, K; Penttilä, PA; Potthast, A; Serimaa, R; Sixta, H; Testova, L, 2014
)
1.12
"The oxalic acid pretreatment of deacetylated biomass was carried out and the hydrolysate directly used for ethanol production without detoxification."( Enhanced bioethanol production from yellow poplar by deacetylation and oxalic acid pretreatment without detoxification.
Kundu, C; Lee, HJ; Lee, JW, 2015
)
1.13
"Oxalic acid treatment apparently alleviated CI development and membrane damage; maintained higher levels of ATP and ADP; increased activities of succinic dehydrogenase (SDH), Ca(2+)-adenosine triphosphatase (Ca(2+)-ATPase) and H(+)-adenosine triphosphatase (H(+)-ATPase); and elevated lycopene accumulation associated with the upregulation of PSY1 and ZDS expression in tomatoes during a period at room temperature following exposure to chilling stress."( Alleviation of chilling injury in tomato fruit by exogenous application of oxalic acid.
Li, P; Song, L; Yin, F; Zheng, X, 2016
)
1.39
"Oxalic acid treatment caused the removal of all single arabinose unit branch chains and some di/trisaccharide branch chains, producing lightly substituted xylan backbone fragments, most of which were in the oligosaccharide (DP < 10) size range."( Elevated propionate and butyrate in fecal ferments of hydrolysates generated by oxalic acid treatment of corn bran arabinoxylan.
Cantu-Jungles, TM; Hamaker, BR; Kaur, A; Keshavarzian, A; Patterson, JA; Reuhs, BL; Rumpagaporn, P, 2016
)
1.38
"Pretreatment with oxalic acid significantly improved the mechanical disintegration of chitin into nanofibers, the length of nanofibers reached ∼1100 nm, and the crystallinity and thermal stability of the chitin were basically unchanged with mild treatment."( One-Step Preparation of Chitin Nanofiber Dispersion in Full pH Surroundings Using Recyclable Solid Oxalic Acid and Evaluation of Redispersed Performance.
Fan, Y; Liu, L; Ma, H; Yu, J, 2021
)
1.16
"Treatment with oxalic acid caused similar reductions in Enterobacteriaceae counts."( Inhibitory effect of oxalic acid on bacterial spoilage of raw chilled chicken.
Anang, DM; Bakar, J; Beuchat, LR; Radu, S; Rusul, G, 2006
)
0.99

Toxicity

ExcerptReferenceRelevance
" In addition, each of the metabolites tested were significantly less developmental toxic than the parent compound, trichloroethylene."( Evaluation of the developmental toxicity of trichloroethylene and detoxification metabolites using Xenopus.
Bantle, JA; Fort, DJ; Hull, M; Rayburn, JR; Stover, EL, 1993
)
0.29
" Despite weathered fibers appearing less toxic than "stored/laboratory" ones, NOA is to be considered far from safe because of fibrous nature and residual surface reactivity."( The effect of weathering on ecopersistence, reactivity, and potential toxicity of naturally occurring asbestos and asbestiform minerals.
Compagnoni, R; Enrico Favero-Longo, S; Fubini, B; Piervittori, R; Tomatis, M; Turci, F, 2009
)
0.35
"The results of this study indicated that cell viability recorded by the 45S5 bioglass paste group did not differ significantly from those of the Caviton, glass ionomer or superseal, moreover pulpal cells microscopic analysis revealed that 45S5 bioglass elicited minimal toxic effect."( Cytotoxicity of 45S5 bioglass paste used for dentine hypersensitivity treatment.
Bakry, AS; Kasugai, S; Ohya, K; Otsuki, M; Tagami, J; Tamura, Y, 2011
)
0.37
" The results from this study suggest that the Fenton oxidation process could remove sulfadiazine, but also increase solution toxicity due to the presence of more toxic products."( Chemical oxidation of sulfadiazine by the Fenton process: kinetics, pathways, toxicity evaluation.
Li, WJ; Xiao, AG; Yang, JF; Ying, GG; Zhou, SB, 2014
)
0.4
" However, most conventional AgNPs syntheses require the use of hazardous chemicals and generate toxic organic waste."( 'Chocolate' silver nanoparticles: Synthesis, antibacterial activity and cytotoxicity.
Chowdhury, NR; MacGregor-Ramiasa, M; Majewski, P; Vasilev, K; Zilm, P, 2016
)
0.43
"Asbestos fibers are highly toxic (Group 1 carcinogen) due to their high aspect ratio, durability, and the presence of iron."( Siderophore-mediated iron removal from chrysotile: Implications for asbestos toxicity reduction and bioremediation.
Casper, B; Christofidou-Solomidou, M; Gonneau, C; Mohanty, SK; Pietrofesa, RA; Salamatipour, A; Willenbring, JK, 2018
)
0.48
" IVAA synergy with simultaneous mEHT is safe and the concomitant application significantly increases the plasma AA level for NSCLC patients."( The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer.
Gui, X; Lu, Y; Ou, J; Pang, CLK; Wang, J; Wang, X; Zhang, H; Zhang, T; Zhang, X; Zhao, C; Zhu, X, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" The biological half-life of [14C]oxalate, estimated by the cumulative excretion of 14C in urine after equilibrium had been established, was 128 min (range: 113-142)."( Renal clearance of [14C]oxalate: comparison of constant-infusion with single-injection techniques.
Boer, P; Endeman, HJ; Mees, EJ; Oei, HY; Prenen, JA; Spoor, SM, 1982
)
0.26
" Pharmacokinetic parameters including Cmax, Tmax, AUC, and betat((1/2)) were determined for EG and GA."( Dose-dependent nonlinear pharmacokinetics of ethylene glycol metabolites in pregnant (GD 10) and nonpregnant Sprague-Dawley rats following oral administration of ethylene glycol.
Bartels, MJ; Carney, EW; Pottenger, LH, 2001
)
0.31
" The development and evaluation of the PBPK model was based upon previously published pharmacokinetic studies coupled with measured blood and tissue partition coefficients and rates of in vitro metabolism of glyoxylic acid to oxalic acid, glycine and other metabolites using primary hepatocytes isolated from male Wistar rats and humans."( Extension of a PBPK model for ethylene glycol and glycolic acid to include the competitive formation and clearance of metabolites associated with kidney toxicity in rats and humans.
Bartels, MJ; Corley, RA; Creim, J; Hansen, SC; McMartin, KE; Saghir, SA; Snellings, WM, 2011
)
0.55
" Pharmacokinetic studies on rats showed that the glutarate salt exhibits doubled plasma AUC values in a single dose within an hour compared to the citrate salt."( Salt and cocrystals of sildenafil with dicarboxylic acids: solubility and pharmacokinetic advantage of the glutarate salt.
Desiraju, GR; Ganguly, S; Sanphui, P; Tothadi, S, 2013
)
0.39
" Pharmacokinetic profiles were obtained when they received solely IVAA and when IVAA in combination with mEHT."( The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer.
Gui, X; Lu, Y; Ou, J; Pang, CLK; Wang, J; Wang, X; Zhang, H; Zhang, T; Zhang, X; Zhao, C; Zhu, X, 2017
)
0.46

Bioavailability

The objectives of this research were to assess the bioavailability of iron in foodstuffs found in the Mexican diet. After binding to calcium in the gut, oxalic acid absorption seems to be inhibited in the presence of calcium. This means that calcium oxalate is poorly absorbed (at least in the upper gastrointestinal tract)

ExcerptReferenceRelevance
" The discussion is focused on toxic levels of hydrocyanate and oxalate, and the significance of the molar ratios in predicting the bioavailability of dietary zinc."( Hydrocyanate, oxalate, phytate, calcium and zinc in selected brands of Nigerian cocoa beverage.
Abara, AE; Aremu, CY, 1992
)
0.28
"Oxalate bioavailability from sugar beet fibre (40 g), spinach (25 g) and a solution of sodium oxalate (182 mg) was tested in nine women using a triplicated 3 x 3 Latin square arrangement."( Bioavailability of oxalic acid from spinach, sugar beet fibre and a solution of sodium oxalate consumed by female volunteers.
Frankos, VH; Hanson, CF; Thompson, WO, 1989
)
0.61
"Studies on effects of fiber, phytic acid, and oxalic acid on mineral bioavailability are reviewed."( Effects of fiber, phytic acid, and oxalic acid in the diet on mineral bioavailability.
Kelsay, JL, 1987
)
0.81
" Calcium bioavailability was nearly 10 times greater for low oxalate kale, CaCO3 and CaCl2 than from CaC2O4 (calcium oxalate) and spinach (high in oxalates)."( Oxalic acid decreases calcium absorption in rats.
Ebner, JS; Krueger, CA; Martin, BR; Weaver, CM, 1987
)
1.72
" In calcium oxalate stone formers, the mean increment of urinary oxalate and the bioavailability following oral sodium oxalate load were significantly higher than in the healthy controls and non-oxalate stone formers."( [Renal oxalate excretion following oral oxalate load in patients with urinary calculus disease and healthy controls].
Ebisuno, S; Fukatani, T; Morimoto, S; Okawa, T; Yasukawa, S; Yoshida, T, 1986
)
0.27
"Spinach was evaluated for its bioavailability of magnesium in the experiment with magnesium-deficient rats."( The bioavailability of magnesium in spinach and the effect of oxalic acid on magnesium utilization examined in diets of magnesium-deficient rats.
Ishii, H; Kikunaga, S; Takahashi, M, 1995
)
0.53
" These results alter our current understanding of calcium bioavailability from foods and therapeutic agents."( Absorption of calcium oxalate does not require dissociation in rats.
Hanes, DA; Heaney, RP; Wastney, M; Weaver, CM, 1999
)
0.3
" The results may be important for elucidating factors affecting iron bioavailability in the small intestine and for the development of foods with improved iron bioavailability."( Organic acids influence iron uptake in the human epithelial cell line Caco-2.
Andlid, T; Salovaara, S; Sandberg, AS, 2002
)
0.31
"The mineral content of legumes is generally high, but the bioavailability is poor due to the presence of phytate, which is a main inhibitor of Fe and Zn absorption."( Bioavailability of minerals in legumes.
Sandberg, AS, 2002
)
0.31
" After binding to calcium in the gut, oxalic acid absorption seems to be inhibited in the presence of calcium and this means that calcium oxalate is poorly absorbed (at least in the upper gastrointestinal tract)."( Urinary oxalic acid excretion differs after oral loading of rats with various oxalate salts.
Hatano, T; Hossain, RZ; Morozumi, M; Ogawa, Y; Sugaya, K, 2003
)
1.02
" Therefore, this study was performed to compare calcium bioavailability and the risk of calcium oxalate stone formation for calcium supplement taken with meal vs."( Schedule of taking calcium supplement and the risk of nephrolithiasis.
Domrongkitchaiporn, S; Ingsathit, A; Prapaipanich, S; Rajatanavin, R; Sopassathit, W; Stitchantrakul, W, 2004
)
0.32
"Oxalate bioavailability is an important determinant of whether the consumption of a particular food is a high risk in individuals predisposed to kidney stones."( Assessment of oxalate absorption from almonds and black beans with and without the use of an extrinsic label.
Chai, W; Liebman, M, 2004
)
0.32
"The investigation was undertaken with the objective of comparing two in vitro techniques, measuring dialyzable iron (method A) and measuring ionizable iron (method B), for iron bioavailability in a model system."( Comparative analysis of influence of promoters and inhibitors on in vitro available iron using two methods.
Gupta, S; Jyothi Lakshmi, A; Prakash, J,
)
0.13
" This mixing state of diacids has important implications for the solubility and cloud nucleation properties of the dominant fraction of water-soluble organics and the bioavailability of iron in dust."( Investigations of the diurnal cycle and mixing state of oxalic acid in individual particles in Asian aerosol outflow.
Prather, KA; Sullivan, RC, 2007
)
0.59
"This paper studied the effects of applying citric acid, oxalic acid and acetic acid on the removal of heavy metals Cd, Pb, Cu and Zn from sewage sludge, and the form transformation and bioavailability of these heavy metals before and after the application of tested organic acids."( [Removal effects of citric acid, oxalic acid and acetic acid on Cd, Pb, Cu and Zn in sewage sludge].
Huang, L; Zhang, QR; Zhou, QX, 2008
)
0.87
"The objectives of this research were to assess the bioavailability of iron in foodstuffs found in the Mexican diet, to provide data on the content of iron absorption inhibitors present in plant origin products and to assess the inhibitory effect of these compounds and of cooking on iron bioavailability; therefore, total content and bioavailable iron, tannins, phytic and oxalic acid were determined in vegetables, cereals, legumes and animal products, before and after cooking."( Role of oxate, phytate, tannins and cooking on iron bioavailability from foods commonly consumed in Mexico.
González-Osnaya, L; Sánchez-Chinchillas, A; Sotelo, A; Trejo, A, 2010
)
0.53
"Organic acids from plant food have been shown to play an important role in the prevention of chronic diseases (osteoporosis, obesity), inherent to western diets, but little is known about their bioavailability in the small intestine, information that needs to be determined in order to quantify likely effects on human health."( Organic acid bioavailability from banana and sweet potato using an in vitro digestion and Caco-2 cell model.
Epriliati, I; Gidley, MJ; Sabboh-Jourdan, H; Valla, F, 2011
)
0.37
" The negative effect of oxalic acid is reducing the bioavailability of calcium and magnesium, and disorder of metabolism of the body's absorption of these elements from the diet."( [The evaluation of anti-nutritive components in beer on the example of oxalic acid].
Baca, E; Baranowski, K; Michałowska, D; Salamon, A, 2012
)
0.92
"The mobility and bioavailability of As combining with amorphous Fe oxides is vulnerable to the environment."( [Chemical extraction of arsenic co-precipitated with amorphous Fe (OH)3 and Fe3O4].
Chen, YP; Jia, YF; Wang, SF, 2013
)
0.39
" Thus, to improve solubility and bioavailability characteristics, cocrystals and salts of the drug have been prepared by treating aliphatic dicarboxylic acids with sildenafil; the N-methylated piperazine of the drug molecule interacts with the carboxyl group of the acid to form a heterosynthon."( Salt and cocrystals of sildenafil with dicarboxylic acids: solubility and pharmacokinetic advantage of the glutarate salt.
Desiraju, GR; Ganguly, S; Sanphui, P; Tothadi, S, 2013
)
0.39
" Tetracyclines form metal-complexes in natural waters, which could reduce their bioavailability for bacterial uptake."( Organic acids enhance bioavailability of tetracycline in water to Escherichia coli for uptake and expression of antibiotic resistance.
Boyd, SA; Li, H; Teppen, BJ; Tiedje, JM; Zhang, Y, 2014
)
0.4
" It can be concluded that by selecting suitable type and concentration of LMWOAs, mobility, and hence, bioavailability of heavy metals can be changed."( Effects of organic acids on cadmium and copper sorption and desorption by two calcareous soils.
Jalali, M; Najafi, S, 2015
)
0.42
" While all three acids elevated the bioavailability of mercury, which increased with the increase of the concentration of acids."( [Effect of Low Molecular Weight Organic Acids on the Chemical Speciation and Activity of Mercury in the Soils of the Water-Level-Fluctuating Zone of the Three Gorges Reservoir].
Deng, H; Liang, L; Qin, CQ; Wang, DY; You, R, 2016
)
0.43
" Therefore, organic ligands played a dominant role in mobility and bioavailability of Cr and the removal of Cr by adsorbents."( Influence of organic acids on kinetic release of chromium in soil contaminated with leather factory waste in the presence of some adsorbents.
Jalali, M; Taghipour, M, 2016
)
0.43
" The results indicate a way to control the size of cocrystals on a nanometer scale, which will provide higher bioavailability of pharmaceuticals."( Raman Spectroscopy of Pharmaceutical Cocrystals in Nanosized Pores of Mesoporous Silica.
Ajito, K; Ohta, R; Ueno, Y, 2017
)
0.46
" Chelates added on 25th d and 25/35th d after sowing, enhanced cadmium (Cd) and zinc (Zn) bioavailability in soil due to complexation."( EDTA and organic acids assisted phytoextraction of Cd and Zn from a smelter contaminated soil by potherb mustard (Brassica juncea, Coss) and evaluation of its bioindicators.
Ali, A; Du, J; Guo, D; Lahori, AH; Li, R; Ren, C; Xiao, R; Zhang, Z, 2019
)
0.51
" The bioavailability of the PTEs in the waste slag increased with decreasing particle size."( Root-induced changes in aggregation characteristics and potentially toxic elements (PTEs) speciation in a revegetated artificial zinc smelting waste slag site.
Luo, Y; Sun, H; Wu, X; Wu, Y, 2020
)
0.56
" The toxicity and bioavailability of aluminum depends mainly on the form in which it occurs."( Chemical Speciation of Aluminum in Wine by LC-ICP-MS.
Frankowski, M; Karaś, K; Zioła-Frankowska, A, 2020
)
0.56
" Oxalic acid and other organic acids will affect the release, immobilization, and bioavailability of Cr(VI) in nature on the mineral surface."( Mobility and transformation of Cr(VI) on the surface of goethite in the presence of oxalic acid and Mn(II).
Fu, F; Liang, C; Tang, B; Zhang, X, 2020
)
1.69
"Rhizosphere acidification in leguminous plants can release P from the dissolution of phosphate compounds which can reduce Pb bioavailability to them via the formation of insoluble Pb compounds in their rhizosphere."( Impacts of oxalic acid-activated phosphate rock and root-induced changes on Pb bioavailability in the rhizosphere and its distribution in mung bean plant.
Adnan Ramzani, PM; Farhad, M; Iqbal, M; Karczewska, A; Khan, MA; Khan, SA; Lewińska, K; Rasool, B; Tauqeer, HM; Turan, V; Ur-Rahman, M; Zubair, M, 2021
)
1.01
" In-vivo experiments proved that the use of cocrystal instead of form I of free API helped to increase the bioavailability ofrivaroxaban."( Explaining dissolution properties of rivaroxaban cocrystals.
Čerňa, I; Hriňová, E; Kozlík, P; Královičová, J; Křížek, T; Roušarová, J; Ryšánek, P; Šíma, M; Skořepová, E; Slanař, O; Šoóš, M, 2022
)
0.72
" The current study examined the role of exogenously applied low molecular weight organic acids (LMWOAs) including oxalic acid (OxA), tartaric acid (TA) and high molecular weight organic acids (HMWOAs) like citric acid (CA) and humic acid (HA) for the bioavailability of Cd in wheat-rice cropping system."( Exogenous application of low and high molecular weight organic acids differentially affected the uptake of cadmium in wheat-rice cropping system in alkaline calcareous soil.
Ahmad, Z; Alharby, HF; Alshamrani, R; Azhar, M; Bamagoos, AA; Bani Mfarrej, MF; Rizwan, M; Usman, M; Zia-Ur-Rehman, M, 2023
)
1.12

Dosage Studied

MyRJ 45 was observed to increase significantly the urinary absorption of 14C in male NMRI mice. It was also found that the mineralization of oxalic acid by electrolysis generated hypochlorite better than the dosage of commercial hypchlorite without electricity. The effects of pH, oxali acid concentration and dosage of the catalyst on the degradation of OII were evaluated.

ExcerptRelevanceReference
" Considerations governing dosage of vitamin C in patients with chronic renal failure are discussed."( The effect of vitamin C intake on plasma oxalate in patients on regular haemodialysis.
Macdougall, AI; McConnell, KM; Modi, KS; Rolton, HA, 1991
)
0.28
" In this study, male Fischer 344 rats were dosed (6 mg/kg) orally with [2-14C]ECH (98% radiochemically pure) as an aqueous solution and killed after 3 days."( Disposition and metabolism of [2-14C]epichlorohydrin after oral administration to rats.
Beatty, PW; Dzidic, I; Gingell, R; Mitschke, HR; Page, AC; Sawin, VL,
)
0.13
" This study compared chemical dosing techniques for recovery of NTM from water samples collected from 115 randomly selected dialysis centers."( Efficacy of chemical dosing methods for isolating nontuberculous mycobacteria from water supplies of dialysis centers.
Bland, LA; Carson, LA; Cusick, LB; Favero, MS, 1988
)
0.27
" MYRJ 45 was observed to increase significantly the urinary absorption of 14C in male NMRI mice when compared to control mice dosed with oxalic acid and water."( Urinary excretion of orally administered oxalic acid in MYRJ 45-treated NMRI mice.
Salminen, E; Salminen, S, 1987
)
0.74
" Dosed animals were kept in metabolism cages for 48 h to monitor urinary and fecal excretion of the label."( Urinary excretion of orally administered oxalic acid in saccharin and o-phenylphenol-fed NMRI mice.
Salminen, E; Salminen, S, 1986
)
0.54
" As vitamin C is a precursor of oxalate in patients on regular hemodialysis, we have measured plasma levels of vitamin C, oxalate, pyridoxine, thiamine and creatinine twice before and 4 weeks after a change of vitamin C dosage in 49 dialysis patients who had been receiving 500 mg of oral vitamin C daily for more than 6 months."( Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients.
Ono, K, 1986
)
0.27
" Chronic daily dosing caused lowering of these metabolites and a delay in the return of lactate to basal levels for 48 hr after the final dose."( Prolonged hypolactatemia and increased total pyruvate dehydrogenase activity by dichloroacetate.
Evans, OB; Stacpoole, PW, 1982
)
0.26
" This inexpensive and comparatively unsophisticated method afforded clear dose-response relationships and good discriminating power."( Measurement of skin-fold thickness in the guinea pig. Assessment of edema-inducing capacity of cutting fluids, acids, alkalis, formalin and dimethyl sulfoxide.
Wahlberg, JE, 1993
)
0.29
" Ethylene glycol was mixed in the diet at concentrations to deliver constant target dosage levels of 0, 50, 150, 500, or 1000 mg/kg/day for 16 weeks to groups of 10 male Wistar and 10 male F-344 rats based on weekly group mean body weights and feed consumption."( Subchronic toxicity of ethylene glycol in Wistar and F-344 rats related to metabolism and clearance of metabolites.
Corley, RA; Cruzan, G; Deyo, JA; Gingell, R; Hard, GC; McMartin, KE; Mertens, JJ; Snellings, WM, 2004
)
0.32
"2% oxalic acid (OA) and 60% sugar solution by trickling method with two alternative types of syringes (an automatic self-filling dosing and a single-use) from the broodright to broodless period."( Efficacy of repeated trickle applications of oxalic acid in syrup for varroosis control in Apis mellifera: influence of meteorological conditions and presence of brood.
Bacandritsos, N; Nanetti, A; Papanastasiou, I; Roinioti, E; Saitanis, C, 2007
)
1.22
" Lower dosage of alpha-FeOOH and higher light intensity increased the photodegradation rate of pyrene."( Photodegradation of polycyclic aromatic hydrocarbon pyrene by iron oxide in solid phase.
Li, FB; Liang, JB; Liu, CP; Liu, CS; Wang, Y, 2009
)
0.35
" It was also found that the mineralization of oxalic acid by electrolysis generated hypochlorite better than the dosage of commercial hypochlorite without electricity."( Oxalic acid mineralization by electrochemical oxidation processes.
Huang, YH; Liu, CH; Shih, YJ, 2011
)
2.07
" The molar ratio of oxalate degraded to ozone consumption increased with increasing catalyst dose and decreasing ozone dosage and pH under the conditions of this study."( Catalytic ozonation of oxalate with a cerium supported palladium oxide: an efficient degradation not relying on hydroxyl radical oxidation.
Croué, JP; Li, W; Zhang, T, 2011
)
0.37
" The yield of oxalic acid is dependent on the amount of ferrous ion dosed since the minimal amount of oxalic acid is formed after the degradation reaction terminates."( Influence of oxalic acid formed on the degradation of phenol by Fenton reagent.
Nakagawa, H; Yamaguchi, E, 2012
)
1.11
" B6 was administered orally starting at 5 mg/kg body weight per day and given in increments of 5 mg/kg every 6 weeks, up to a final dosage of 20 mg/kg per day at week 24."( Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice.
Beck, BB; Franklin, J; Hero, B; Hoppe, B; Hoyer-Kuhn, H; Kohbrok, S; Volland, R, 2014
)
0.4
"The antifungal drug, 5-fluorocytosine (FC), is marketed as a capsule (250 or 500 mg strength) instead of the preferred tablet dosage form."( Enabling tablet product development of 5-fluorocytosine through integrated crystal and particle engineering.
Perumalla, SR; Sun, CC, 2014
)
0.4
"Ethionamide (ETH), a Biopharmaceutics Classification System class II drug, is a second-line drug manufactured as an oral dosage form by Pfizer to treat tuberculosis."( Mechanochemistry applied to reformulation and scale-up production of Ethionamide: Salt selection and solubility enhancement.
da Silva, CC; de Melo, CC; Ellena, J; Pereira, CC; Rosa, PC, 2016
)
0.43
"A batch experiment was conducted to investigate the mobilization of soil-borne arsenic by three common low-molecular-weight organic acids with a focus on dosage and time effects."( Mobilization of soil-borne arsenic by three common organic acids: Dosage and time effects.
Lin, C; Onireti, OO, 2016
)
0.43
" The effects of pH, oxalic acid concentration and dosage of the catalyst on the degradation of OII were evaluated, respectively."( Photodegradation of Orange II using waste paper sludge-derived heterogeneous catalyst in the presence of oxalate under ultraviolet light emitting diode irradiation.
Guo, J; Shi, H; Wan, X; Zhou, G, 2016
)
0.76
" Among these two antibiotics, colistin is considered toxic, and therefore, its clinical use and dosage need cautious approach."( Use of succinic & oxalic acid in reducing the dosage of colistin against New Delhi metallo-β-lactamase-1 bacteria.
Chandar, B; Kumar, R; Parani, M, 2018
)
0.81
" Batch experiments (the effect of Ox concentration, initial Cr(VI) concentration, RS dosage and coexisting ions) in Ox + RS + UV photoreduction system were designed to investigate the reaction process."( The synergetic role of rice straw in enhancing the process of Cr(VI) photoreduction by oxalic acid.
Cao, F; Niu, W; Sun, J; Zhang, L, 2020
)
0.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (2 Product(s))

Product Categories

Product CategoryProducts
Household Essentials2

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Bar Keepers Friend Soft Cleanser Multi-Surface Cream -- 26 fl ozBar Keepers FriendHousehold Essentialscitric acid, citric acid, oxalic acid2024-11-29 10:47:42
Bar Keepers Friend Spray + Foam Multi-Surface Cleaner -- 25.4 fl ozBar Keepers FriendHousehold Essentialscitric acid, citric acid, oxalic acid2024-11-29 10:47:42

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
algal metaboliteAny eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
alpha,omega-dicarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Glyoxylate metabolism and glycine degradation2037
Glycine metabolism06
Biochemical pathways: part I0466

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency15.35530.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency61.65240.000221.22318,912.5098AID743035
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency13.90840.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency61.13060.000229.305416,493.5996AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency19.82340.001024.504861.6448AID743215
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency19.33120.000627.21521,122.0200AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Proto-oncogene Tyrosine-protein Kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00003,500.000030,875.000040,000.0000AID977608
Chain A, Pyruvate kinase, M2 isozymeHomo sapiens (human)Ki24.000024.000024.000024.0000AID977610
Chain A, Phosphonopyruvate hydrolaseVariovorax sp. Pal2Ki17.000017.000017.000017.0000AID977610
Chain A, Phosphoenolpyruvate-protein phosphotransferaseEscherichia coliKi280.0000280.0000280.0000280.0000AID977610
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)IC50 (µMol)40,000.00000.00020.533510.0000AID1797268; AID224309
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (117)

Processvia Protein(s)Taxonomy
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
primary ovarian follicle growthProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of cytokine productionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signal complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
epidermal growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
spermatogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
learning or memoryProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mechanical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to acidic pHProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of gene expressionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of epithelial cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of glucose metabolic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein processingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
skeletal muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of smooth muscle cell migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
macroautophagyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
forebrain developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
T cell costimulationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of protein-containing complex assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein destabilizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to nutrient levelsProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomere maintenance via telomeraseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to insulin stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of intracellular estrogen receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of integrin activationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of toll-like receptor 3 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
adherens junction organizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
substrate adhesion-dependent cell spreadingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of dephosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of hippo signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intracellular signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
entry of bacterium into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
osteoclast developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ERBB2 signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
angiotensin-activated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
odontogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of vascular permeabilityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
stress fiber assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transcytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Notch signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of bone resorptionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of Ras protein signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein autophosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neurotrophin TRK receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
oogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
progesterone receptor signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
leukocyte migrationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of small GTPase mediated signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to mineralocorticoidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
myoblast proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to electrical stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of focal adhesion assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of mitochondrial depolarizationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of telomerase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
uterus developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
branching involved in mammary gland duct morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of cell projection assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
intestinal epithelial cell developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
interleukin-6-mediated signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hydrogen peroxideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
response to interleukin-1Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to lipopolysaccharideProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to peptide hormone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to progesterone stimulusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fatty acidProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to hypoxiaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to fluid shear stressProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of podosome assemblyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
DNA biosynthetic processProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of heart rate by cardiac conductionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell-cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of protein localization to nucleusProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of TORC1 signalingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cellular response to prolactinProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of male germ cell proliferationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of ovarian follicle developmentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of lamellipodium morphogenesisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor-beta signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of early endosome to late endosome transportProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of anoikisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
regulation of caveolin-mediated endocytosisProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell differentiationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
innate immune responseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein phosphorylationProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
symbiont entry into host cellProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
protein kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein kinase C bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
signaling receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
insulin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
integrin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATP bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase activator activityProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
enzyme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
heme bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nuclear estrogen receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
SH2 domain bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phospholipase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
transmembrane transporter bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cadherin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ephrin receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ATPase bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
phosphoprotein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
BMP receptor bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
connexin bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
scaffold protein bindingProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
podosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
nucleoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
mitochondrial inner membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
lysosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
late endosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cytosolProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
actin filamentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
caveolaProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
focal adhesionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
cell junctionProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
ruffle membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
neuronal cell bodyProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic growth coneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
membrane raftProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
perinuclear region of cytoplasmProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
extracellular exosomeProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
synaptic membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
glutamatergic synapseProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
postsynaptic specialization, intracellular componentProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
dendritic filopodiumProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
plasma membraneProto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1597863Non-competitive inhibition of Staphylococcus aureus pyruvate carboxylase expressed in Escherichia coli BL21(DE3) treated with ATP as substrate prior to HCO3-, ATP and NADH addition by Michelis-Menten based double-reciprocal plot analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID679442TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.00476 uM, oxalic acid: 10000 uM) in OATP-B-expressing HEK293 cells2003The Journal of pharmacology and experimental therapeutics, Aug, Volume: 306, Issue:2
Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID224309Inhibitory activity against SH2 domain of human p60 c-Src tyrosine kinase using surface plasmon resonance (SPR) assay.2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1597859Competitive inhibition of Staphylococcus aureus pyruvate carboxylase expressed in Escherichia coli BL21(DE3) treated with pyruvate as substrate prior to HCO3-, ATP and NADH addition by Michelis-Menten based double-reciprocal plot analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Evaluation of α-hydroxycinnamic acids as pyruvate carboxylase inhibitors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1797268Scintillation Proximity Assay (SPA) from Article 10.1021/jm020970s: \\Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.\\2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2006Biochemistry, Sep-26, Volume: 45, Issue:38
Structure and kinetics of phosphonopyruvate hydrolase from Variovorax sp. Pal2: new insight into the divergence of catalysis within the PEP mutase/isocitrate lyase superfamily.
AID1811Experimentally measured binding affinity data derived from PDB2006Biochemistry, Sep-26, Volume: 45, Issue:38
Structure and kinetics of phosphonopyruvate hydrolase from Variovorax sp. Pal2: new insight into the divergence of catalysis within the PEP mutase/isocitrate lyase superfamily.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2006Proceedings of the National Academy of Sciences of the United States of America, Oct-31, Volume: 103, Issue:44
Structure of phosphorylated enzyme I, the phosphoenolpyruvate:sugar phosphotransferase system sugar translocation signal protein.
AID1811Experimentally measured binding affinity data derived from PDB2006Proceedings of the National Academy of Sciences of the United States of America, Oct-31, Volume: 103, Issue:44
Structure of phosphorylated enzyme I, the phosphoenolpyruvate:sugar phosphotransferase system sugar translocation signal protein.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005Biochemistry, Jul-12, Volume: 44, Issue:27
Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,000)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990573 (28.65)18.7374
1990's266 (13.30)18.2507
2000's366 (18.30)29.6817
2010's613 (30.65)24.3611
2020's182 (9.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 78.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index78.98 (24.57)
Research Supply Index7.67 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index211.40 (26.88)
Search Engine Supply Index2.96 (0.95)

This Compound (78.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials54 (2.59%)5.53%
Reviews82 (3.94%)6.00%
Case Studies57 (2.74%)4.05%
Observational1 (0.05%)0.25%
Other1,889 (90.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]